Filtered By:
Specialty: Pharmaceuticals
Cancer: Cancer
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 41 results found since Jan 2013.
Women: Don't Use Aspirin For Routine Prevention Of Heart Attacks, Stroke, And Cancer
Although once widely recommended, aspirin for the prevention of a first heart attack or stroke (primary prevention) has lost favor in recent years, as the large number of bleeding complications appeared to offset the reduction in cardiovascular events. But at the same time evidence has emerged demonstrating the long-term effect of aspirin in preventing colorectal cancer, leading some to think that the risk-to-benefit equation for aspirin should be reconsidered.
Source: Forbes.com Healthcare News - December 5, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
Cancer Tied to Higher Risk for Deadly Stroke
FRIDAY, Dec. 6, 2019 -- The risk for a deadly stroke is higher in cancer patients and cancer survivors than the general public, according to a study published online Nov. 15 in Nature Communications.
Nicholas G. Zaorsky, M.D., from Penn State in...
Source: Drugs.com - Pharma News - December 6, 2019 Category: Pharmaceuticals Source Type: news
Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Nancy Brown
Credentials: CEO, American Heart AssociationBio: Nancy Brown has been Chief Executive Officer of the American Heart Association (AHA) since 2009. The Association is widely known and highly respected as the world’s largest voluntary health organization dedicated to preventing, treating and defeating cardiovascular diseases and stroke.
During her tenure as CEO, the AHA has become a global leader in the discovery and dissemination of heart disease and stroke science. Notably, under Nancy’s leadership the Association announced its bold new 2020 health impact goal: To improve the cardiovascular health of all...
Source: PHRMA - June 24, 2013 Category: Pharmaceuticals Authors: rlowe Source Type: news
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Making Sense of Nutraceuticals in China
The Chinese nutraceutical market is considered the third largest in the world after the US and Japan, or the fourth largest if Europe is counted as a single market.Despite strong fundamentals and high rates of annual growth, though, the Chinese market remains some way from realizing its true potential. Its evolution is muddied by ambiguities around what nutraceuticals actually are and how they should be managed.The result has been polarization between over-zealous regulation of so-called health foods, and a grey market where products have skirted approval procedures through questionable positioning or by exploiting alterna...
Source: EyeForPharma - February 10, 2017 Category: Pharmaceuticals Authors: Marc Yates Source Type: news
When Disease Can Bring On Stress Disorder
Post-traumatic stress disorder, or PTSD, most often associated with soldiers returning from the battle front, is increasingly being diagnosed in people with medical conditions from stroke and heart attack to cancer.
Source: WSJ.com: Health - June 24, 2013 Category: Pharmaceuticals Tags: FREE Source Type: news
If you could propose one idea to help improve health care delivery in the United States, what would it be?
Thumbnail: Tags: conversationsphrma conversationslarry hausnermyrl weinbergchris hansennancy brownContributors: 11621161115911631173Contributions: Read Larry Hausner's bio
Despite the rapid development of innovative technologies in the health care field, we have yet to discover a panacea that will easily transform our health care system into one that provides high-quality and cost-effective care. What we have discovered and come to agree on over the last decade is that our sick care system must be reconfigured to a health care system that emphasizes wellness and prevention. For that reason, I offer ...
Source: PHRMA - June 24, 2013 Category: Pharmaceuticals Authors: rlowe Source Type: news
Every day, thousands of Americans turn 65. How do we help ensure that the U.S. system is ready to meet their needs?
Thumbnail: Tags: conversationsphrma conversationsMedicareseniorsmary grealybob blancatofreda lewis hallconversations 2Contributors: 118611871184Contributions: Read Freda Lewis-Hall's bio
The most impactful action we can take is to move to a prevention-centered system, with policies and programs in place to preserve good health and prevent disabling disease. There is no reason why age 65 shouldn’t be the gateway to years of general good health. We have to get people in the Baby Boom generation thinking now about how they can stay vigorous and delay, for as long as possible, the issues that come when...
Source: PHRMA - July 2, 2013 Category: Pharmaceuticals Authors: Stephen Source Type: news
America's Next Great Prescription
Scientists have made a discovery that is proven to reduce premature death from heart attacks and stroke, lower the risk of diabetes and certain cancers, control blood pressure, prevent osteoporosis, and alleviate symptoms of depression and anxiety.
Source: Forbes.com Healthcare News - January 16, 2014 Category: Pharmaceuticals Authors: Robert Pearl, M.D. Source Type: news
Cynthia A. Bens
Vice President, Public PolicyCynthia Bens is the Vice President of Public Policy at the not-for-profit Alliance for Aging Research in Washington, D.C. In this capacity, Ms. Bens is responsible for guiding the organization’s federal policy work, representing the Alliance in multiple national coalitions, and directing all aspects of the Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) and Aging in Motion (AIM) coalitions. Ms. Bens sits on the Alliance for a Stronger FDA Board of Directors and is a Founding Executive Committee Member of Friends of the National Institute on Aging (FoNIA). She has served on the...
Source: PHRMA - June 17, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news
